{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:45:25Z","timestamp":1784547925680,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LEO Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is a lack of consensus related to the collection of standardized data for individuals with vitiligo enrolled in clinical trials and registries as well as those seen in clinical practice which causes difficulty in accurately interpreting, comparing, and pooling of data.<\/jats:p>\n                <jats:p>Several years ago, efforts to initiate work on developing core outcome sets were performed and a consensus was reached in 2015 on the first core domain set for vitiligo clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>This project aims to further develop a core outcome set for vitiligo clinical trials as well as create internationally agreed-upon core outcome sets for registries and clinical practice. These core outcome sets will include a core domain set and a core measurement instruments set and will be supplemented by contextual factors, including baseline and treatment-related characteristics. In a preparatory exercise, the 2015 core domain set will be re-evaluated and will serve as the basis for the list of outcome domains used to initiate the consensus process. This project will consist of two parts. Part 1 will focus on the selection of a core domain set, or \u201cwhat to measure\u201d and contextual factors, for each setting based on electronic surveys (e-Delphi technique) and a conclusive consensus meeting by a large group of international stakeholders. Part 2 will include selection of core measurement instruments, or \u201chow to measure,\u201d and measurement details (e.g., scale and timing) for the core domain sets and contextual factors agreed upon in part 1. Part 2 will be based on consensus meetings with stakeholders involved in part 1 and will be guided by C3 (CHORD-COUSIN Collaboration), Harmonising Outcome Measures for Eczema (HOME), COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN), and Outcome Measures in Rheumatology (OMERACT) recommendations including information on measurement properties of available instruments (systematic review and expert\/patient opinion). At the end of part 2, all stakeholders involved will be invited to participate in a final meeting in which the ultimate core data sets (core outcome sets and contextual factors) will be presented and the dissemination plan and implementation goals will be defined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This project will harmonize data collection between clinical trials, registries, and clinical practices, facilitating new insights in vitiligo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study is registered in the <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.comet-initiative.org\/Studies\/Details\/2074\">Core Outcome Measures for Effectiveness Trials (COMET)<\/jats:ext-link> database and on the <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.c3outcomes.org\/voice\">C3 (CHORD-COUSIN Collaboration)<\/jats:ext-link> website.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06497-1","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T11:02:43Z","timestamp":1658574163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-8195","authenticated-orcid":false,"given":"Nanja","family":"van Geel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wolkerstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline B.","family":"Terwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Meurant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Eleftheriadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"6497_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","volume":"167","author":"V Eleftheriadou","year":"2012","unstructured":"Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol. 2012;167:804\u201314.","journal-title":"Br J Dermatol"},{"key":"6497_CR2","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/archdermatol.2012.3065","volume":"148","author":"C Vrijman","year":"2012","unstructured":"Vrijman C, Linthorst Homan MW, Limpens J, van der Veen W, Wolkerstorfer A, Terwee CB, et al. Measurement properties of outcome measures for vitiligo. A systematic review. Arch Dermatol. 2012;148:1302\u20139.","journal-title":"Arch Dermatol"},{"issue":"5","key":"6497_CR3","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/bjd.14356","volume":"174","author":"M Whitton","year":"2016","unstructured":"Whitton M, Pinart M, Batchelor JM, Leonardi-Bee J, Gonzalez U, Jiyad Z, et al. Evidence-based management of vitiligo: summary of a Cochrane systematic review. Br J Dermatol. 2016 May;174(5):962\u20139.","journal-title":"Br J Dermatol"},{"key":"6497_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/pcmr.12354","volume":"28","author":"V Eleftheriadou","year":"2015","unstructured":"Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, et al. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res. 2015;28:363\u20139.","journal-title":"Pigment Cell Melanoma Res"},{"key":"6497_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.17013","volume":"180","author":"V Eleftheriadou","year":"2019","unstructured":"Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, et al. International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol. 2019;180:574\u20139.","journal-title":"Br J Dermatol"},{"key":"6497_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1207\/s15326934crj1704_6","volume":"17","author":"C Asmus","year":"2005","unstructured":"Asmus C, James K. Nominal Group Technique, Social Loafing, and Group Creative Project Quality. Creativity Res J. 2005;17:349\u201354.","journal-title":"Creativity Res J"},{"key":"6497_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1440-172X.2012.02017.x","volume":"18","author":"N Harvey","year":"2012","unstructured":"Harvey N, Holmes CA. Nominal group technique: an effective method for obtaining group consensus. Int J Nurs Pract. 2012;18:188\u201394.","journal-title":"Int J Nurs Pract"},{"key":"6497_CR8","first-page":"70","volume":"32","author":"M Potter","year":"2004","unstructured":"Potter M, Gordon S, Hamer P. The Nominal Group Technique: A useful consensus methodology in physiotherapy research. N Z J Physiother. 2004;32:70\u20135.","journal-title":"N Z J Physiother"},{"issue":"5","key":"6497_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018 May;27(5):1147\u201357.","journal-title":"Qual Life Res."},{"key":"6497_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1745-6215-15-247","volume":"15","author":"CAC Prinsen","year":"2014","unstructured":"Prinsen CAC, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a \u201ccore outcome set.\u201d. Trials. 2014;15:247.","journal-title":"Trials"},{"key":"6497_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","volume":"17","author":"CAC Prinsen","year":"2016","unstructured":"Prinsen CAC, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a \u201cCore Outcome Set\u201d \u2013 a practical guideline. Trials. 2016;17:449.","journal-title":"Trials"},{"key":"6497_CR12","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1111\/ajd.13008","volume":"60","author":"ML Peralta-Pedrero","year":"2019","unstructured":"Peralta-Pedrero ML, Morales-S\u00e1nchez MA, Jurado-Santa Cruz F, De la Torre-Garc\u00eda ME, Cruz-Peralta ES, Olgu\u00edn-Garc\u00eda MG. Systematic Review of Clinimetric Instruments to determine the severity of Non-segmental Vitiligo. Aust J Dermatol. 2019;60:e178\u201385.","journal-title":"Aust J Dermatol"},{"key":"6497_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/jid.2014.320","volume":"135","author":"J Schmitt","year":"2015","unstructured":"Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M, et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2015;135:24\u201330.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 3","key":"6497_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: version 1.0. Trials. 2017;18(Suppl 3):280.","journal-title":"Trials"},{"issue":"1","key":"6497_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaad.2019.03.009","volume":"81","author":"CAC Prinsen","year":"2019","unstructured":"Prinsen CAC, Spuls PI, Kottner J, Thomas KS, Apfelbacher C, Chalmers JR, et al. Navigating the landscape of core outcome set development in dermatology. J Am Acad Dermatol. 2019;81(1):297\u2013305.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"6497_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/pcmr.12593","volume":"30","author":"N van Geel","year":"2017","unstructured":"van Geel N, Boniface K, Seneschal J, Jacquemin C, Speeckaert R, Wolkerstorfer A, et al. Meeting report: Vitiligo Global Issues Consensus Conference Workshop \"Outcome measurement instruments\" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd. Pigment Cell Melanoma Res. 2017;30(4):436\u201343.","journal-title":"Pigment Cell Melanoma Res"},{"key":"6497_CR17","first-page":"1733","volume":"23","author":"CB Terwee","year":"2014","unstructured":"Terwee CB, Roorda LD, de Vet HCW, Dekker J, Westhovens R, van Leeuwen J, et al. Dutch-Flemish translation of 17 item banks from the Patient Reported Outcomes Measurement Information System (PROMIS). Qual Lif Res. 2014;23:1733\u201341.","journal-title":"Qual Lif Res"},{"issue":"3","key":"6497_CR18","first-page":"304","volume":"11","author":"RC Gershon","year":"2010","unstructured":"Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D. The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas. 2010;11(3):304\u201314.","journal-title":"J Appl Meas."},{"key":"6497_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64:395\u2013400.","journal-title":"J Clin Epidemiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06497-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T11:12:07Z","timestamp":1658574727000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06497-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6497"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06497-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the Ethics Committee (UZ Gent, Belgium) has been obtained. Registration number (B): B6702020000867.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Dr. N van Geel is an investigator\/consultant\/advisor for Abbvie, Pfizer, Incyte, Sun Pharma\u00a0and MSD\/Merck.Prof. Dr. Ph.I. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), receives departmental independent research grants for TREAT NL registry, for which she is Chief Investigator (CI), from pharma companies since December 2019, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, e.g., psoriasis and atopic dermatitis, for which financial compensation is paid to the department\/hospital.Dr. Garg is an advisor for AbbVie, Aclaris Therapeutics, Anaptys Bio, Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, InflaRx, Insmed, Janssen, Novartis, Pfizer, UCB, and Viela Biosciences, and receives honoraria. Dr Garg receives research grants from AbbVie, UCB and National Psoriasis Foundation. Amit Garg ORCID ID: CB Terwee is one of the founders of the COSMIN initiative.Prof. Dr. K Ezzedine is a consultant for Abbvie, VielBio, Incyte, Pfizer and Pierre Fabre.Dr. A Pandya is a consultant for Abbvie, Arcutis, Avita, Chromaderm, Incyte, Pfizer, Viela Bio, Villaris, Immune Tolerance Network, and Twi and holds stock options with Zerigo Health and Tara Medical.Dr. I Hamzavi AbbVie, fees consulting; Clinuvel, principal investigator, research funding to institution; Incyte, principal investigator, research funding, and consultant fees paid personally; Pfizer Inc., principal investigator and consultant; Avita, PI, research funding.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"591"}}